{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:48Z","timestamp":1792834728214,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aims to investigate emerging signals and clinical characteristics associated with adverse event reports of respiratory, thoracic, and mediastinal diseases (RTMD) related to proprotein convertase subtilisin\/kexin 9 inhibitors (PCSK9i) in the FDA Adverse Event Reporting System (FAERS) database. PCSK9i-related RTMD adverse event reports were extracted from the FAERS database (covering the period from the first quarter of 2016 to the fourth quarter of 2023), and the clinical characteristics and onset times of these reports were analyzed. The reporting odds ratio (ROR) and the Bayesian Confidence Propagation Neural Network (BCPNN) were used to calculate disproportionate signals in the adverse event reports. A total of 17,063 PCSK9i-related RTMD adverse event reports were extracted from the FAERS database. A summary of these reports revealed that the median age of the reported population was 68 years (interquartile range: 61\u201374 years); the proportion of female patients was higher than that of male patients (56.53% vs 40.56%). The United States submitted the highest number of adverse event reports (n\u2005=\u200515,031, 88.09%), followed by Germany (n\u2005=\u20051076, 6.31%). The median time to onset for adverse event reports was 7.5 days (interquartile range\u2005=\u20050.5\u201377.5 days); the median time to onset for reports related to alirocumab was 14.5 days (interquartile range\u2005=\u20051.5\u2013100.5 days), while for evolocumab it was only 6.5 days (interquartile range\u2005=\u20050.5\u201370.5 days). Disproportionate analysis of adverse event reports revealed signals for both evolocumab (ROR\u2005=\u20051.18, 95% CI: 1.16\u20131.20; information component [IC]\u2005=\u20050.35, IC\n                      <jats:sub>025<\/jats:sub>\n                      \u2005=\u20050.33) and alirocumab (ROR\u2005=\u20051.50, 95% CI: 1.45\u20131.55; IC\u2005=\u20050.41, IC\n                      <jats:sub>025<\/jats:sub>\n                      \u2005=\u20050.38). Among these, rhinorrhea, cough, oropharyngeal pain, nasal congestion, and dysphonia were the most frequently reported preferred terms (PTs). The results of this study indicate the presence of a disproportionate signal of RTMD adverse events associated with PCSK9i in the FAERS database; however, this merely suggests that such events warrant further attention in reports related to PCSK9i and does not establish a causal relationship between the 2.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050089","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:58Z","timestamp":1787968918000},"page":"e50089","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective study of disproportionality analysis signals between proprotein convertase subtilisin\/kexin 9 inhibitor use and respiratory, thoracic, and mediastinal disorders"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4792-3322","authenticated-orcid":false,"given":"Hongzhu","family":"Chen","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK9 inhibitors: a real-world experience.","volume":"105","author":"G\u00fcrg\u00f6ze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation.","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jacl.2019.07.005","article-title":"PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: challenges at the crossroads.","volume":"13","author":"Annemans","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R6-20261024","first-page":"641","article-title":"A systematic review of PCSK9 inhibitors alirocumab and evolocumab.","volume":"22","author":"McDonagh","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (A PCSK9 monoclonal antibody) from 14 randomized trials.","volume":"118","author":"Jones","year":"2016","journal-title":"Am J Cardiol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.numecd.2022.07.020","article-title":"A subgroup analysis of the ODYSSEY APPRISE study: safety and efficacy of alirocumab in the Italian cohort.","volume":"32","author":"Cefal\u00f9","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials.","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia.","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS).","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data.","volume":"14","author":"Hauben","year":"2009","journal-title":"Drug Discov Today"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"111758","DOI":"10.1016\/j.biopha.2021.111758","article-title":"PCSK9 and cancer: rethinking the link.","volume":"140","author":"Mahboobnia","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"100426","DOI":"10.1016\/j.jlr.2023.100426","article-title":"PCSK9 and the nervous system: a no-brainer?","volume":"64","author":"Jaafar","year":"2023","journal-title":"J Lipid Res"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"953845","DOI":"10.3389\/fphar.2022.953845","article-title":"Sex difference in circulating PCSK9 and its clinical implications.","volume":"13","author":"Jia","year":"2022","journal-title":"Front Pharmacol"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.expneurol.2014.01.023","article-title":"Anxiety vulnerability in women: a two-hit hypothesis.","volume":"259","author":"Catuzzi","year":"2014","journal-title":"Exp Neurol"},{"key":"R24-20261024","doi-asserted-by":"crossref","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS.","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"106814","DOI":"10.1016\/j.phrs.2023.106814","article-title":"The burden of hypercholesterolemia and ischemic heart disease in an ageing world.","volume":"193","author":"Pirillo","year":"2023","journal-title":"Pharmacol Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:02:03Z","timestamp":1792832523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":23,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050089","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}